Nomura/Instinet analyst, Christopher Marai, reiterated his Buy on Biogen (NASDAQ: BIIB) and slighly upped his numbers ahead of 2Q18 results ...

This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE